Document is current
Any future updates will be listed below
-
Authors
,
Iolascon, Giovanni https://orcid.org/0000-0002-0976-925X
Vitacca, Michele
Carraro, Elena https://orcid.org/0000-0002-1259-1050
Chisari, Carmelo https://orcid.org/0000-0002-1043-7738
Fiore, Pietro
Messina, Sonia https://orcid.org/0000-0001-7994-3391
Mongini, Tiziana
Moretti, Antimo https://orcid.org/0000-0002-4598-2891
Sansone, Valeria A. https://orcid.org/0000-0002-1354-3800
Toscano, Antonio https://orcid.org/0000-0002-3995-4827
Siciliano, Gabriele https://orcid.org/0000-0002-6142-2384
- License Information
-
More Information
Article History
Received: 28 June 2019
Accepted: 25 November 2019
First Online: 7 December 2019
Compliance with ethical standards
:
: GI, MV, EC, PF, SM, and AM have no conflicts of interest to declare. CC has served as an expert in a scientific meeting for Sanofi Genzyme.TM has served as an expert in scientific boards for Sanofi Genzyme. VAS has served as scientific expert on advisory boards for Biogen, Avexis, Sarepta, Santhera, and PTC Therapeutics and declares no conflict of interest for this project. AT has received some reimbursement from Sanofi Genzyme for assisting in teaching courses and for being a member of the Global Pompe Registry committee. GS has served as scientific expert and supervisor for a study grant on Pompe disease supported by Sanofi in 2018 and in the current year.
